Zeltiq Aesthetics Inc. (ZLTQ) Shares Down 1.3%
Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ) shares dropped 1.3% on Monday . The company traded as low as $39.88 and last traded at $39.94, with a volume of 299,110 shares trading hands. The stock had previously closed at $40.47.
ZLTQ has been the subject of several analyst reports. TheStreet downgraded shares of Zeltiq Aesthetics from a “buy” rating to a “hold” rating in a report on Friday, June 10th. Brean Capital reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Zeltiq Aesthetics in a report on Tuesday, June 21st. Leerink Swann reaffirmed a “buy” rating on shares of Zeltiq Aesthetics in a report on Thursday, June 30th. Zacks Investment Research downgraded shares of Zeltiq Aesthetics from a “hold” rating to a “sell” rating in a report on Thursday, July 14th. Finally, Maxim Group raised their price objective on shares of Zeltiq Aesthetics from $40.00 to $48.00 and gave the stock a “buy” rating in a report on Tuesday, August 9th. Three research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $39.89.
The firm’s 50 day moving average is $37.50 and its 200-day moving average is $30.52. The company has a market cap of $1.54 billion, a PE ratio of 58.60 and a beta of 0.80.
Zeltiq Aesthetics (NASDAQ:ZLTQ) last released its quarterly earnings data on Monday, August 8th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.05) by $0.07. Zeltiq Aesthetics had a net margin of 9.54% and a negative return on equity of 9.90%. The company had revenue of $89.50 million for the quarter, compared to analysts’ expectations of $79.68 million. During the same period in the previous year, the firm earned $0.03 earnings per share. The firm’s revenue for the quarter was up 38.9% on a year-over-year basis. On average, equities analysts expect that Zeltiq Aesthetics Inc. will post ($0.13) earnings per share for the current year.
In other news, VP Bradley Hauser sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, July 11th. The shares were sold at an average price of $30.02, for a total transaction of $90,060.00. Following the completion of the transaction, the vice president now directly owns 47,184 shares of the company’s stock, valued at $1,416,463.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Carl Lamm sold 3,125 shares of the business’s stock in a transaction that occurred on Thursday, September 15th. The shares were sold at an average price of $40.00, for a total transaction of $125,000.00. Following the transaction, the vice president now directly owns 28,251 shares of the company’s stock, valued at $1,130,040. The disclosure for this sale can be found here. Insiders own 15.60% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Handelsinvest Investeringsforvaltning acquired a new stake in shares of Zeltiq Aesthetics during the first quarter valued at about $272,000. Texas Permanent School Fund acquired a new stake in shares of Zeltiq Aesthetics during the first quarter valued at about $695,000. Nisa Investment Advisors L.L.C. acquired a new stake in shares of Zeltiq Aesthetics during the first quarter valued at about $1,575,000. Prudential Financial Inc. acquired a new stake in shares of Zeltiq Aesthetics during the first quarter valued at about $2,049,000. Finally, BlackRock Group LTD raised its stake in shares of Zeltiq Aesthetics by 278.1% in the first quarter. BlackRock Group LTD now owns 30,785 shares of the company’s stock valued at $837,000 after buying an additional 22,642 shares during the period.
About Zeltiq Aesthetics
ZELTIQ Aesthetics, Inc is a medical technology company. The Company focuses on developing and commercializing products utilizing its controlled-cooling technology platform. Its product, the CoolSculpting System, is designed to reduce stubborn fat bulges. It sell the CoolSculpting system primarily to dermatologists, plastic surgeons, aesthetic specialists, and obstetrics and gynecology physicians.
Receive News & Ratings for Zeltiq Aesthetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zeltiq Aesthetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.